Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues (Q38257364)

1 September 2017

1 reference

title

Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues (English)

1 reference

1 September 2017

8

Andreas von Deimling

0 references

Adelheid Wöhrer

object named as

Adelheid Wöhrer

3

0 references

Matthias Preusser

object named as

Matthias Preusser

9

0 references

Priscilla K Brastianos

object named as

Priscilla K Brastianos

7

0 references

author name string

Anna Sophie Berghoff

1

1 reference

1 September 2017

Rupert Bartsch

2

1 reference

1 September 2017

Berthold Streubel

4

1 reference

1 September 2017

Peter Birner

5

1 reference

1 September 2017

Johan M Kros

6

1 reference

1 September 2017

7 October 2014

1 reference

1 September 2017

Acta Neuropathologica

1 reference

1 September 2017

128

1 reference

1 September 2017

6

1 reference

1 September 2017

879-891

1 reference

https://scigraph.springernature.com/pub.10.1007/s00401-014-1350-7

1 September 2017

0 references

cites work

Endocrine-responsive breast cancer and strategies for combating resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Optimal management of brain metastases from breast cancer. Issues and considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Breast cancer brain metastases responding to primary systemic therapy with T-DM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

EGFR mutation status in brain metastases of non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

National Working Group Meeting on ALK diagnostics in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Frequent EGFR mutations in brain metastases of lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Intrapatient homogeneity of BRAFV600E expression in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

PD-L1 expression in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

GNAQ and GNA11 mutations in melanocytomas of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Epidemiology of brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Current approaches to the treatment of metastatic brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Brain metastasis: opportunity for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Brain metastases: pathobiology and emerging targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

ROS1 translocations and amplifications in lung cancer brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Immunotherapy in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

PET imaging of oestrogen receptors in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1350-7

10.1007/S00401-014-1350-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference